This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Factor II [prothrombin] deficiency제2인자[프로트롬빈]의 결핍 (제이인자프로트롬빈결핍증)

ItemDetails
A. Classification codesICD-10: D68.2 / Special Copayment Reduction: V009
B. SynonymsProthrombin deficiency, Hypoprothrombinemia, Dysprothrombinemia, Congenital prothrombin deficiency
C. Adult onsetNot low — mild cases are sometimes first discovered in adulthood through excessive bleeding after surgery or childbirth
1. History2. Causes
3. Genetics4. General epidemiology
5. Pathophysiology6. Symptoms
7. Signs8. Screening
9. Diagnosis10. Treatment
11. Prognosis12. Prevention
13. References

1. History

Discovery of prothrombin

Prothrombin (factor II, FII) is one of the proteins with the longest history in coagulation research. In the 1890s, Alexis Morawitz explained blood coagulation as "the process by which thrombin converts fibrinogen to fibrin" and first formalized the concept of prothrombin, the precursor of thrombin. Later, in the 1940s, when Quick developed the prothrombin time (PT) test, prothrombin became established as a central indicator of clinical coagulation testing. The prothrombin time is still used today as a key tool for liver function, monitoring anticoagulant therapy, and preoperative risk assessment.

Identification of congenital deficiency

The first reliable clinical report of congenital prothrombin deficiency was made by Quick himself in 1947. However, some early cases described simply as "prothrombin deficiency" actually included deficiencies of other coagulation factors. With advances in techniques for isolating individual coagulation factors from the 1960s onward, true congenital prothrombin deficiency (hypoprothrombinemia) and functional abnormalities (dysprothrombinemia) began to be distinguished.

Molecular understanding and discovery of the FII 20210G>A variant

In 1996, Poort et al. discovered that the G20210A variant, located in the 3' untranslated region (3'-UTR) of the prothrombin gene (F2), markedly increases the risk of venous thrombosis. This variant leads in the exact opposite direction from deficiency, namely to excess prothrombin production, and it is a common thrombosis risk factor, with 2~3% of Europeans being heterozygous carriers. This made it clear that variants of the prothrombin gene can cause pathology in both directions: "deficiency (bleeding)" and "excess (thrombosis)."


2. Causes

Congenital causes

Congenital prothrombin deficiency is caused by pathogenic variants in the F2 gene (chromosome 11p11.2). Complete prothrombin deficiency (prothrombin level 0%) is lethal at the embryonic stage and is therefore not observed in surviving patients. The congenitally deficient patients seen clinically all have either hypoprothrombinemia with residual activity or dysprothrombinemia due to structural abnormalities of the protein. The main variant types reported are missense variants, splicing variants, and small insertions/deletions.

Acquired causes

Because prothrombin is a vitamin K-dependent coagulation factor, acquired deficiency due to vitamin K deficiency (neonatal period, malabsorption syndromes, long-term antibiotic therapy) and administration of vitamin K antagonists (VKAs) such as warfarin is much more frequent in clinical practice. Liver failure also causes reduced prothrombin synthesis in hepatocytes, and in disseminated intravascular coagulation (DIC) prothrombin decreases due to increased consumption. In some autoimmune diseases (lupus, antiphospholipid antibody syndrome), autoantibodies against prothrombin are produced, rarely causing acquired hypoprothrombinemia.

Relationship between warfarin and prothrombin

Warfarin inhibits vitamin K epoxide reductase (VKOR), interfering with carboxylation of the vitamin K-dependent coagulation factors (II, VII, IX, X). Among these, prothrombin (FII) has the longest half-life, at about 60~72 hours, so FII is the last to decrease early in warfarin administration and the last to recover after warfarin is stopped. In this respect, FII plays a central role in using PT (INR) as an indicator of stable anticoagulant effect. In patients with congenital FII deficiency, using warfarin or VKAs further suppresses prothrombin and can be very dangerous.


3. Genetics

F2 gene structure

The F2 gene is located on chromosome 11p11.2 and consists of 14 exons. The prothrombin protein is a single polypeptide of about 72 kDa consisting of 579 amino acids and is synthesized in hepatocytes. The protein structure consists of an N-terminal Gla domain (site of vitamin K-dependent γ-carboxylation), two kringle domains, and a C-terminal serine protease domain. In the Gla domain, 10 glutamic acid residues are γ-carboxylated, which is essential for phospholipid membrane binding via calcium ion binding.

Mode of inheritance

Congenital prothrombin deficiency follows an autosomal recessive mode of inheritance. Clinically significant deficiency occurs in carriers of homozygous or compound heterozygous variants. Heterozygous carriers show prothrombin activity at about 50% of normal and are mostly asymptomatic or show only a mild bleeding tendency. However, symptoms may appear when heterozygous carriers are double heterozygous (digenic) or have a combined deficiency of other coagulation factors. Because complete absence of prothrombin in homozygous deficiency is embryonically lethal, all reported patients have severe partial deficiency with residual activity or functional abnormality.

Contrast between the FII 20210G>A variant and deficiency

An important F2 gene variant in the opposite direction from congenital deficiency is FII 20210G>A (rs1799963). This variant is located in the 3'-UTR, increases mRNA stability, and increases prothrombin synthesis by about 30%. As a result, blood prothrombin levels rise and the risk of venous thromboembolism (VTE) increases 2~4-fold. The heterozygous frequency is common, at about 2~3%, in populations of European descent, and together with the factor V Leiden (FV Leiden) variant it is the most common congenital thrombosis risk factor. That variants of the same gene thus cause opposite phenotypes—deficiency (bleeding) and excess (thrombosis)—is clinically very important.


4. General epidemiology

Incidence and prevalence

Congenital prothrombin deficiency is a very rare bleeding disorder, with a worldwide prevalence estimated at about 1/2,000,000~1/3,000,000. This places it among the rarest of the rare coagulation factor deficiencies. According to 2012 European Network of Rare Bleeding Disorders (EN-RBD) registry data, prothrombin deficiency accounts for about 0.5~1% of all registered patients with rare coagulation factor deficiencies. Relatively high incidence is reported in regions where consanguineous marriage is frequent, such as Iran and Pakistan.

Sex and age characteristics

Because congenital prothrombin deficiency is autosomal recessive, it occurs equally in males and females. Severe deficiency (FII activity <1%) presents from the neonatal period with umbilical cord bleeding and intracranial hemorrhage and is diagnosed early. Patients with mild deficiency (FII activity 10~50%) or dysprothrombinemia may go undiagnosed until adulthood in the absence of particular hemostatic stress and are found incidentally through excessive bleeding after surgical procedures or delivery.

Frequency of acquired hypoprothrombinemia

Acquired hypoprothrombinemia is much more common than the congenital form. In particular, acquired hypoprothrombinemia associated with antiphospholipid antibody syndrome (APS) is not uncommonly encountered in clinical practice. The mechanism is that when lupus anticoagulant (LA) is present in APS, direct antibodies against prothrombin form and rapidly clear prothrombin, resulting in hypoprothrombinemia. In this case, both aPTT and PT are prolonged, accompanied by a positive DRVVT (dilute Russell viper venom time).


5. Pathophysiology

Normal activation pathway of prothrombin

Prothrombin is synthesized in the liver and then circulates in the blood as an inactive precursor. When the extrinsic or intrinsic coagulation pathway is activated, ultimately a prothrombinase complex composed of FXa-FVa-Ca²⁺ forms on phospholipid membranes (the surface of activated platelets or sites of endothelial injury). This complex cleaves prothrombin to generate active thrombin (FIIa). Thrombin performs diverse roles: ① conversion of fibrinogen → fibrin, ② platelet activation (PAR receptors), ③ activation of FV, FVIII, and FXIII, and ④ activation of protein C through thrombomodulin binding (anticoagulant feedback).

Pathophysiology of deficiency

When prothrombin decreases, thrombin generation is insufficient and the entire coagulation process is limited. When FII activity is less than 1%, severe spontaneous bleeding occurs, and at less than 10%, excessive bleeding occurs even with minor trauma. Mild deficiency with FII activity of 10~50% may pass without routine bleeding symptoms. In dysprothrombinemia, protein antigen is normal but an abnormal protein with reduced activity circulates, and with some variants the abnormal thrombin competitively blocks the substrate-binding sites of normal thrombin (dominant negative effect), producing a more severe phenotype.

Vitamin K dependence and mechanism of action of warfarin

Vitamin K-dependent coagulation factors, including prothrombin, require γ-carboxylation of glutamic acid residues in the Gla domain to enable Ca²⁺-mediated phospholipid binding. When vitamin K is deficient, this carboxylation is incomplete and nonfunctional proteins called PIVKA (proteins induced by vitamin K absence) are produced. Warfarin blocks this pathway and lowers all vitamin K-dependent factors simultaneously; among them, FII has the longest half-life and is the second most important target after FVII within the therapeutic dose range. Using warfarin in congenital FII deficiency causes an extreme risk of bleeding through additional FII suppression.


6. Symptoms

Symptoms of severe deficiency

In severe deficiency with FII activity below 1–10%, early bleeding symptoms are prominent. Umbilical cord bleeding in the neonatal period, intracranial hemorrhage (ICH) in infancy, hemarthrosis and intramuscular hematoma are typical symptoms. Intracranial hemorrhage is the most serious complication and, when it occurs in the neonatal period, can lead to neurological sequelae or death. Mucosal bleeding (oral, nasal, gastrointestinal), nontraumatic hematuria and heavy menstrual bleeding (in female patients) are also common. A characteristic pattern is failure of hemostasis after trauma or surgery.

Symptoms of mild deficiency and dysprothrombinemia

In mild deficiency with FII activity of 10–50% or in dysprothrombinemia, spontaneous bleeding is rare, and excessive bleeding occurs mainly after hemostatic stress such as surgery, trauma, dental procedures or childbirth. Some patients complain of heavy menstrual bleeding, delayed postoperative wound healing or recurrent epistaxis and are discovered incidentally by a prolonged PT. Dysprothrombinemia has a highly variable phenotype, ranging from asymptomatic carriers to severe bleeding and, rarely, a thrombotic tendency.

Symptoms of acquired hypoprothrombinemia

Acquired hypoprothrombinemia associated with antiphospholipid antibody syndrome can cause serious bleeding, and paradoxically a thrombotic tendency may coexist in the same patient, complicating treatment decisions. In acquired hypoprothrombinemia due to warfarin overdose, the bleeding risk rises sharply in proportion to the INR increase. In vitamin K deficiency of the newborn (hemorrhagic disease of the newborn), multiple vitamin K-dependent factors including prothrombin are also reduced simultaneously, causing widespread bleeding.


7. Signs

Physical examination findings

Physical examination findings in prothrombin deficiency vary with severity. In severe deficiency, extensive ecchymoses of the limbs, localized swelling from intramuscular hematoma, and joint swelling and functional limitation from hemarthrosis are observed. With recurrent hemarthrosis, findings of degenerative arthritis due to articular cartilage damage progress. With recurrent gastrointestinal bleeding, signs of anemia (pallor, tachycardia) may appear. Neurological sequelae after intracranial hemorrhage (hemiplegia, speech disorder, visual field defects) may also be found on physical examination.

Laboratory findings

The most characteristic laboratory finding in prothrombin deficiency is simultaneous prolongation of PT (prothrombin time) and aPTT (activated partial thromboplastin time). This is because prothrombin is located in the common pathway and affects both the extrinsic (PT) and intrinsic (aPTT) pathways. In the mixing test, correction with normal plasma suggests deficiency, whereas failure to correct suggests the presence of an inhibitor. Fibrinogen and TT are normal, which distinguishes it from fibrinogen deficiency. The diagnosis is confirmed by a specific factor assay (measurement of FII activity).

Imaging findings

With recurrent hemarthrosis, joint X-rays show joint space narrowing, subchondral cysts and bone erosion. Intramuscular hematomas appear on ultrasound or MRI as masses with blood signal characteristics. Intracranial hemorrhage is identified on brain CT as a hyperdense hematoma and on MRI by signal changes according to the oxidation state of the blood. When intra-abdominal bleeding is suspected, abdominal CT may show free fluid and hematoma.


8. Screening

First-line screening: PT and aPTT

Screening for prothrombin deficiency is done through the finding of simultaneous prolongation of PT and aPTT on standard coagulation screening tests. When both PT and aPTT are prolonged, abnormalities of the common pathway (FI, FII, FV, FX) or of multiple coagulation factors are considered first. A normal TT excludes fibrinogen abnormalities, after which differential diagnosis proceeds with individual factor assays. PT is also expressed standardized as the INR, and in patients not on anticoagulant therapy a PT INR of 1.5 or higher suggests a significant coagulation abnormality.

Mixing test

When PT or aPTT is prolonged, the mixing test, in which patient plasma is mixed 1:1 with normal plasma and retested, is a key step in distinguishing deficiency from an inhibitor. If deficiency is the cause, PT/aPTT corrects immediately after mixing; if an inhibitor (autoantibody, lupus anticoagulant) is the cause, it does not correct. Time-dependent inhibitors (e.g., FVIII inhibitors) are seen more clearly when remeasured after 2 hours of incubation at 37°C.

Specific factor assays

When screening tests suggest a common pathway abnormality, a specific factor assay that measures the activity of each factor individually is performed. FII activity is measured by a clot-based assay using FII-deficient plasma as substrate or by a chromogenic substrate assay. Comparing antigen levels with activity distinguishes dysprothrombinemia (normal antigen, reduced activity) from hypoprothrombinemia (both antigen and activity reduced).


9. Diagnosis

Diagnostic criteria

Diagnosis of congenital prothrombin deficiency is confirmed in four steps: ① simultaneous prolongation of PT and aPTT, ② reduced FII activity on specific factor assay (defined as below 50% of normal; severe is below 10%), ③ exclusion of acquired causes such as vitamin K, liver function and DIC, and ④ genetic analysis (identification of a pathogenic variant in the F2 gene). Diagnosis of dysprothrombinemia requires FII antigen/activity discordance and genetic analysis. Direct identification of the variant protein by prothrombin mass spectrometry is also possible.

Differential diagnosis

The differential diagnosis of simultaneous PT and aPTT prolongation should consider the following: ① vitamin K deficiency (FII, FVII, FIX and FX all reduced; rapid correction after vitamin K administration), ② liver failure (reduction of multiple coagulation factors, reduced fibrinogen, reduced albumin), ③ DIC (elevated D-dimer, thrombocytopenia, accompanied by hemorrhagic anemia), ④ antiphospholipid antibody syndrome (positive lupus anticoagulant and anticardiolipin antibodies, acquired hypoprothrombinemia), and ⑤ combined factor deficiencies (such as combined FVII+FX deficiency). Checking for warfarin use is also essential.

Genetic counseling and family testing

Because it is an autosomal recessive disorder, the parents of a confirmed patient are likely to be heterozygous carriers, and FII activity testing is recommended for them. Siblings may have homozygous or compound heterozygous variants, so screening tests are performed. For patients planning pregnancy, the possibility of prenatal genetic diagnosis is discussed. Distinguishing it from the FII 20210G>A variant is also an important part of genetic counseling.


10. Treatment

Prothrombin complex concentrate (PCC)

The main treatment for congenital prothrombin deficiency is prothrombin complex concentrate (PCC). PCC contains concentrated vitamin K-dependent coagulation factors (FII, FVII, FIX, FX) and can rapidly correct FII levels by intravenous injection. Both 3-factor PCC (Beriplex, Octaplex) and 4-factor PCC contain FII and can therefore be used. The target FII level depends on the bleeding situation; 25–30% or higher is recommended for serious bleeding and 20–30% for surgery.

Fresh frozen plasma (FFP)

When PCC is unavailable, fresh frozen plasma (FFP) is an alternative. FFP contains all coagulation factors and can be used to correct FII, but large volumes are required, with a risk of volume overload. In adults, raising FII by 10–15% requires 15–20 mL/kg of FFP. FFP requires blood group matching and takes time to thaw, which limits immediate administration in emergencies.

Prophylactic treatment and management of special situations

In patients with severe prothrombin deficiency, regular prophylactic PCC injections can be considered, and the long half-life of FII (60–72 hours) works favorably in setting an appropriate prophylactic dosing interval. At delivery, FII levels are maintained at least at 20–30% or higher before delivery, and in the newborn FII levels are monitored along with vitamin K supplementation. In patients with dysprothrombinemia and a thrombotic tendency, anticoagulant therapy (DOAC, heparin) is applied cautiously while balancing it against the bleeding risk. In patients with congenital deficiency, drugs that inhibit platelet function, such as NSAIDs and aspirin, are avoided.


11. Prognosis

Prognosis of severe deficiency

In severe deficiency with FII activity below 1–5%, the risk of death from intracranial hemorrhage and serious internal bleeding is high without appropriate treatment. However, when an appropriate prophylaxis and treatment system using PCC is in place, long-term survival is possible and quality of life also improves greatly. With recurrent hemarthrosis, arthropathy (hemophilic arthropathy) may progress, requiring physical therapy and orthopedic intervention.

Prognosis of mild deficiency and dysprothrombinemia

Patients with mild deficiency with FII activity of 10–50% or with dysprothrombinemia often bleed excessively only under hemostatic stress, so with appropriate preoperative management and regular follow-up they can live almost the same life as the general population. In the thrombotic phenotype of dysprothrombinemia, recurrent thrombosis determines the prognosis, and long-term anticoagulant therapy may be needed.

Prognosis of acquired hypoprothrombinemia

The prognosis of acquired hypoprothrombinemia associated with antiphospholipid antibody syndrome depends on the response of the underlying disease to treatment. Recovery is possible when there is a good response to steroid or immunosuppressive treatment. Acquired hypoprothrombinemia due to warfarin or vitamin K antagonists is rapidly corrected by stopping the drug or administering vitamin K.


12. Prevention

Regular follow-up and prophylactic dosing plan

Patients with severe prothrombin deficiency need regular follow-up with coagulation tests (PT, INR, FII activity). Thanks to the long half-life of FII (60–72 hours), prophylactic administration of PCC is possible once or twice a week or even less often. Prophylactic PCC aims to maintain the FII trough level at 15–20% or higher. During prophylactic treatment, the risk of thrombotic complications from activated coagulation factors contained in PCC must be monitored.

Preparation before surgery and trauma

Before any surgery or invasive procedure, FII activity is measured and a plan for PCC or FFP administration to reach the target level is established in advance. Even for minor procedures such as dental surgery and endoscopy, prior replacement is needed if FII levels are low. FII levels are monitored continuously during and after surgery, with additional doses as needed. Patients are educated to always inform medical staff of their history of coagulation factor deficiency on admission.

Genetic counseling and lifestyle guidance

Confirmed patients and their families receive information through genetic counseling on carrier status, the likelihood of transmission to children, prenatal diagnosis and related matters. In daily life, they are advised to avoid contact sports or activities with a high bleeding risk, and it is emphasized that they must report their history of a bleeding disorder whenever they visit a new medical facility. Vitamin K intake is kept stable (with caution during deficient vegetable intake or long-term antibiotic therapy), and self-medication with drugs that inhibit platelet function, such as NSAIDs and aspirin, is avoided.


13. References

  1. Lancellotti S, De Cristofaro R. Congenital prothrombin deficiency. Semin Thromb Hemost. 2009;35(4):367-381.
  2. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88(10):3698-3703.
  3. Peyvandi F, Palla R, Menegatti M, et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost. 2012;10(4):615-621.
  4. Butenas S, Mann KG. Blood coagulation. Biochemistry (Mosc). 2002;67(1):3-12.
  5. Girolami A, Scarano L, Saggiorato G, et al. Congenital deficiencies and abnormalities of prothrombin. Blood Coagul Fibrinolysis. 1998;9(7):557-569.
  6. Bernardi F, Liney DL, Patracchini P, et al. Molecular defects in CRM+ prothrombin deficiency: distance analysis of point mutations using a linear model of the 3D protein structure. Br J Haematol. 1994;86(3):597-603.
  7. Segal JB, Dzik WH. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion. 2005;45(9):1413-1425.
  8. Miyawaki Y, Suzuki A, Fujita J, et al. Thrombosis from a prothrombin mutation conveying antithrombin resistance. N Engl J Med. 2012;366(25):2390-2396.
  9. Rosendaal FR, Reitsma PH. Genetics of venous thrombosis. J Thromb Haemost. 2009;7(Suppl 1):301-304.
  10. Mumford AD, Ackroyd S, Alikhan R, et al. Guideline for the diagnosis and management of the rare coagulation disorders. Br J Haematol. 2014;167(3):304-326.
  11. Esmon CT. The protein C pathway. Chest. 2003;124(3 Suppl):26S-32S.
  12. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med. 2011;365(2):147-156.